Advertisement

Uremic Toxins pp 135-140 | Cite as

The Fraction b 4-2: Isolation, Characterization and Biological Activities with Reference to Uremic Polyneuropathy

  • N. K. Man
  • G. Cueille
  • P. Faguer
  • J. Boudet
  • D. Pierrat
  • J. Zingraff
  • A. Sausse
  • J. L. Funck-Brentano
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 223)

Abstract

The toxic role of numerous compounds accumulated in the body fluids of uremic patients is not well established. Instead of comparing the overall chromatographic plasma pattern of uremic patients to that of healthy subjects (1), one uremic symptom, namely active recent polyneuritis, was chosen and the correlation between the evolution of symptoms and biochemical patterns as modified by hemodialysis was evaluated. This correlation was complemented by a bioassay in which the fraction isolated previously exhibits a specific in vitro activity similar to that observed in vivo. These clinical, biochemical and bioassay techniques each contribute to form a correlative approach (2). Uremic polyneuritis was chosen to test the “middle molecule hypothesis” because it was found to respond favorably to any method which increases middle molecule transfer, i.e., more frequent or more prolonged dialysis or the use of a more porous membrane (3). In six patients with progressive and complete motor nerve paraplegia due to inadequate dialysis, the rapid improvement of nervous symptoms when using a dialysis membrane highly permeable to middle molecules brought us the first clinical evidence for the validity of the hypothesis (4).

Keywords

Free Diet Uremic Toxin Action Potential Amplitude High Liquid Performance Chroma Motor Nerve Conduction Velocity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. FÜRST, L. ZIMMERMAN, J. BERGSTROM. Determination of endogenous middle molecules in normal and uremic body fluids. Clin. Nephrol. 5:178, 1976.Google Scholar
  2. 2.
    J.L. FUNCK-BRENTANO, G. CUEILLE, N.K. MAN. A defense of the moddle molecule hypothesis. Kidney Int. 13 (Suppl. 8):S31, 1978.Google Scholar
  3. 3.
    A.L. BABB, P.C. FARRELL, D.A. UVELLI, B.H. SCRIBNER. Hemodialyzer evaluation by examination of solute molecular spectra. Trans. Am. Soc. Artif. Intern. Organs 18:98, 1972.CrossRefGoogle Scholar
  4. 4.
    N.K. MAN, B. TERLAIN, J. PARIS, G. WERNER, A. SAUSSE, J.-L. FUNCK- BRENTANO. An approach to “middle molecules” identification in artificial kidney dialysate, with reference to neuropathy prevention. Trans. Am. Soc. Artif. Intern. Organs 19:320, 1973.PubMedCrossRefGoogle Scholar
  5. 5.
    G. CUEILLE. Mise en evidence et evaluation des “Moyennes Molecules” de la taille de la Vitamine B12 presentes dans les liquides biologiques de sujets normaux et de patients uremiques. J. Chromatogr. 146:55,1978.PubMedCrossRefGoogle Scholar
  6. 6.
    G. CUEILLE, N.K. MAN, A. SAUSSE, J.P. FARGES, J.L. FUNCK-BRENTANO. Further characterization of a neurotoxic uremic molecule, in “Proceedings 8th International Congress of Nephrology,” W. ZURUKZOGLOU, M. PAPADIMITRIOU, M. PYRPASOPOULOS, M. SION, ed., S. Karger, Basel, 1981.Google Scholar
  7. 7.
    N.K. MAN, G. CUEILLE, J. ZINGRAFF, T. DRUEKE, P. JÜNGERS, A. SAUSSE, J. BOUDET, J.L. FUNCK-BRENTANO. Evaluation of plasma neurotoxin concentration in uraemic Polyneuropathie patients. Proc. Eur. Dial. Transplant Assoc. 15:164, 1978.PubMedGoogle Scholar
  8. 8.
    N.K. MAN, G. CUEILLE, J. ZINGRAFF, J. BOUDET, A. SAUSSE, J.L. FUNCK-BRENTANO. Uremic neurotoxin in the middle molecular weight range. Artificial Organs 4:116, 1980.PubMedCrossRefGoogle Scholar
  9. 9.
    N.K. MAN, C. VERGER, P. FAGUER, J. VANTELON, J.L. FUNCK-BRENTANO. Middle molecule b 4–2 removal rate in patients on continuous ambulatory peritoneal dialysis, in: “Advances in Peritoneal Dialysis”, G.M. GAEL, M. KESSEL, K.D. NOLPH, ed., Excerpta Medica, Amsterdam, 1981.Google Scholar
  10. 10.
    P. FAGUER, N.K. MAN, G. CUEILLE, S. DI GIULIO, J.L. FUNCK-BRENTANO. Improved separation and quantification of the “middle molecule” b 4–2 in uremia. Clin. Chem. 29:703, 1983.PubMedGoogle Scholar
  11. 11.
    J. BOUDET, G. CUEILLE, J.M. BENOISTN, K. MAN, J.L. FUNCK-BRENTANO. In vitro frog sural nerve test: a monitor for detecting nerutoxin solutes. Artificial Organs 4 (Suppl): 94, 1980.CrossRefGoogle Scholar
  12. 12.
    J. BOUDET, N.K. MAN, G. CUEILLE, Y. LEGRAIN, J.L. FUNCK-BRENTANO. Relationship between plasma concentration of middle molecular weight fraction b, motor nerve conduction velocity and plasma creatinine in experimental chronic renal failure in rats. Artificial Organs 4 (Suppl):115, 1980.Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • N. K. Man
    • 1
    • 3
  • G. Cueille
    • 2
    • 3
  • P. Faguer
    • 1
    • 3
  • J. Boudet
    • 1
    • 3
  • D. Pierrat
    • 1
    • 3
  • J. Zingraff
    • 1
    • 3
  • A. Sausse
    • 1
    • 3
  • J. L. Funck-Brentano
    • 1
    • 3
  1. 1.Department of NephrologyNecker HospitalParisFrance
  2. 2.Rhône-Poulenc Research CenterParisFrance
  3. 3.ParisFrance

Personalised recommendations